Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL: Tosedostat in elderly refractory/relapsed AML
NCT00780598Phase 2Completed
- Sponsor
- Chroma Therapeutics
- Start
- Oct 2009
- Primary completion
- Mar 2011
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of tosedostat in acute myeloid leukemia (AML), sponsored by Chroma Therapeutics. Started Oct 2009; status: completed.
02
Drugs
tosedostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00780598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00780598.